Celltrion Patent-Cliff Exposure & CMS Drug Spending Portfolio

Celltrion (US): 11 reconciled FDA prescription therapies, $160.1M 2024 CMS Part D & Medicaid spend, and $9,865 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies11
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$160.1M
2024 Medicare Part D Spend$69.5M
2024 Medicaid Spend$90.6M
California HCAI SB 17 FilingsSpecialty launch notice ($9,865 intro WAC)